Cargando…

Pharmacotherapies for COPD

This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejiofor, Stan, Turner, Alice M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653890/
https://www.ncbi.nlm.nih.gov/pubmed/23700381
http://dx.doi.org/10.4137/CCRPM.S7211
_version_ 1782269469394993152
author Ejiofor, Stan
Turner, Alice M
author_facet Ejiofor, Stan
Turner, Alice M
author_sort Ejiofor, Stan
collection PubMed
description This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
format Online
Article
Text
id pubmed-3653890
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36538902013-05-22 Pharmacotherapies for COPD Ejiofor, Stan Turner, Alice M Clin Med Insights Circ Respir Pulm Med Expert Review This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines. Libertas Academica 2013-04-25 /pmc/articles/PMC3653890/ /pubmed/23700381 http://dx.doi.org/10.4137/CCRPM.S7211 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
spellingShingle Expert Review
Ejiofor, Stan
Turner, Alice M
Pharmacotherapies for COPD
title Pharmacotherapies for COPD
title_full Pharmacotherapies for COPD
title_fullStr Pharmacotherapies for COPD
title_full_unstemmed Pharmacotherapies for COPD
title_short Pharmacotherapies for COPD
title_sort pharmacotherapies for copd
topic Expert Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653890/
https://www.ncbi.nlm.nih.gov/pubmed/23700381
http://dx.doi.org/10.4137/CCRPM.S7211
work_keys_str_mv AT ejioforstan pharmacotherapiesforcopd
AT turneralicem pharmacotherapiesforcopd